ARWR Stock Analysis: Arrowhead Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 7.896m USD | 12M Return: 48.8% | US04280A1007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 127M
Qual. Beats: 0
Rev. Trend: 62.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arrowhead Pharmaceuticals is a clinical-stage biotechnology company that develops RNA interference (RNAi)-based therapeutics aimed at silencing disease-causing genes to treat intractable conditions. The company, founded in 2003 and headquartered in Pasadena, California, has a pipeline spanning Phase 1 through Phase 3 trials, with lead candidates Plozasiran and Zodasiran in Phase 3 development for lipid-related disorders (APOC3 and ANGPTL3 targets, respectively). Its broader pipeline addresses liver diseases, cardiometabolic conditions, complement-mediated disorders, and central nervous system indications.
Arrowhead generates value through a hybrid model of internal clinical development alongside major collaboration and licensing agreements with large pharmaceutical partners, including GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics. Such partnerships are common in the biotechnology sector and typically provide milestone payments, royalties, and funding in exchange for development and commercialization rights to specific candidates or territories.
- Plozasiran Phase 3 PALISADE data readout approaches for severe hypertriglyceridemia
- Royalty revenue from GSK and Takeda collaborations expands pipeline value
- Cash runway and dilution risk remain key investor concerns
| Net Income: -320.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -0.96 > 1.0 |
| NWC/Revenue: 207.3% < 20% (prev 126.1%; Δ 81.21% < -1%) |
| CFO/TA -0.03 > 3% & CFO -59.1m > Net Income -320.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (143.4m) vs 12m ago 3.12% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 38.34% > 50% (prev 43.21%; Δ -4.87% > 0%) |
| Interest Coverage Ratio: -1.72 > 6 (EBIT TTM -159.5m / Interest Expense TTM 92.6m) |
| A: 0.66 (Total Current Assets 1.67b - Total Current Liabilities 283.3m) / Total Assets 2.11b |
| B: -0.91 (Retained Earnings -1.92b / Total Assets 2.11b) |
| C: -0.09 (EBIT TTM -159.5m / Avg Total Assets 1.75b) |
| D: 0.28 (Book Value of Equity 465.5m / Total Liabilities 1.65b) |
| Altman-Z'' = 1.03 = BB |
| DSRI: 0.79 (Receivables 8.56m/9.70m, Revenue 669.5m/596.6m) |
| GMI: 1.00 (GM 96.22% / 96.43%) |
| AQI: 0.88 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.12 (Revenue 669.5m / 596.6m) |
| TATA: -0.12 (NI -320.0m - CFO -59.1m) / TA 2.11b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of October 20, 2026, the stock is trading at USD 57.23 with a total of 1,646,800 shares traded. Over the past week, the price has changed by -5.76%, over one month by -16.80%, over three months by -20.13% and over the past year by +48.77%.
Current recommended Stop Loss: 52.40 (which is 8.4% or 1.7 ATR below the current price).
Arrowhead Pharmaceuticals has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy ARWR.
- StrongBuy: 10
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 107.7 | 88.2% |
P/E Forward = 111.1111
P/S = 11.7942
P/B = 20.5512
P/EG = -1.32
Revenue TTM = 669.5m USD
EBIT TTM = -159.5m USD
EBITDA TTM = -133.7m USD
Long Term Debt = 824.1m USD (from longTermDebt, last quarter)
Short Term Debt = 40.0m USD (from shortTermDebt, last quarter)
Debt = 983.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 119.6m
Net Debt = -345.9m USD (calculated: Debt 983.7m - CCE 1.33b)
Enterprise Value = 7.55b USD (7.90b + Debt 983.7m - CCE 1.33b)
Interest Coverage Ratio = -1.72 (Ebit TTM -159.5m / Interest Expense TTM 92.6m)
EV/FCF = -39.25x (Enterprise Value 7.55b / FCF TTM -192.4m)
FCF Yield = -2.55% (FCF TTM -192.4m / Enterprise Value 7.55b)
FCF Margin = -28.74% (FCF TTM -192.4m / Revenue TTM 669.5m)
Net Margin = -47.79% (Net Income TTM -320.0m / Revenue TTM 669.5m)
Gross Margin = unknown ((Revenue TTM 669.5m - Cost of Revenue TTM 23.9m) / Revenue TTM)
Tobins Q-Ratio = 3.57 (Enterprise Value 7.55b / Total Assets 2.11b)
Interest Expense / Debt = 9.41% (Interest Expense 92.6m / Debt 983.7m)
Taxrate = 41.56% (21.4m / 51.5m)
NOPAT = -93.2m (EBIT -159.5m * (1 - 41.56%)) [loss with tax shield]
Current Ratio = 5.37 (Total Current Assets 1.67b / Total Current Liabilities 311.1m)
Debt / Equity = 2.11 (Debt 983.7m / totalStockholderEquity, last quarter 465.5m)
Debt / EBITDA = 2.59 (negative EBITDA) (Net Debt -345.9m / EBITDA -133.7m)
Debt / FCF = 1.80 (negative FCF - burning cash) (Net Debt -345.9m / FCF TTM -192.4m)
Total Stockholder Equity = 528.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.32% (Net Income -320.0m / Total Assets 2.11b)
RoE = -60.54% (Net Income TTM -320.0m / Total Stockholder Equity 528.5m)
RoCE = -11.79% (EBIT -159.5m / Capital Employed (Equity 528.5m + L.T.Debt 824.1m))
RoIC = -5.08% (negative operating profit) (NOPAT -93.2m / Invested Capital 1.84b)
WACC = 12.00% (E(7.90b)/V(8.88b) * Re(12.81%) + D(983.7m)/V(8.88b) * Rd(9.41%) * (1-Tc(0.42)))
Discount Rate = 12.81% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 93.99 | Cagr: 6.94%
[DCF] Fair Price = unknown (Cash Flow -192.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: 62.87 | Revenue CAGR: 195.1% | SUE: 0.20 | # QB: 0
EPS current Quarter (2026-12-31): EPS=-1.37 | Chg30d=-1.66% | Revisions=-25% | Analysts=7
EPS current Year (2026-09-30): EPS=-3.51 | Chg30d=+0.73% | Revisions=-67% | GrowthEPS=-35034.2% | GrowthRev=-44.0%
EPS next Year (2027-09-30): EPS=-4.98 | Chg30d=-3.60% | Revisions=-67% | GrowthEPS=-41.7% | GrowthRev=-29.3%
[Analyst] Revisions Ratio: -81% (up=0, down=13)